Each year, about 60,000 adults 65 and older are hospitalized with R.S.V.
The Centers for Disease Control and Prevention estimated that in one year, more than 21,000 people in that age group would need to take the GSK vaccine to prevent one R.S.V.
Several treatments, including a maternal vaccine and a monoclonal antibody for infants against R.S.V., are under agency review.
The GSK vaccine, called Arexvy, was nearly 83 percent effective against severe R.S.V.
The final vote of the F.D.A.’s advisory panel in favor of the Pfizer vaccine’s safety and efficacy was 7 to 4.
Persons:
Miller Fisher, Jerica Pitts
Organizations:
Disease Control, GSK, Pfizer, Infants, R.S.V